84 related articles for article (PubMed ID: 18429960)
1. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor.
Saito Y; Yasunaga M; Kuroda J; Koga Y; Matsumura Y
Cancer Sci; 2008 Jun; 99(6):1258-64. PubMed ID: 18429960
[TBL] [Abstract][Full Text] [Related]
2. Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
Saito Y; Yasunaga M; Kuroda J; Koga Y; Matsumura Y
Eur J Cancer; 2010 Feb; 46(3):650-8. PubMed ID: 20015633
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
4. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Saito Y; Matsumura Y
Int J Cancer; 2009 Jun; 124(11):2505-11. PubMed ID: 19189401
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
[TBL] [Abstract][Full Text] [Related]
7. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
[TBL] [Abstract][Full Text] [Related]
8. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.
Sumitomo M; Koizumi F; Asano T; Horiguchi A; Ito K; Asano T; Kakizoe T; Hayakawa M; Matsumura Y
Cancer Res; 2008 Mar; 68(6):1631-5. PubMed ID: 18339841
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
[TBL] [Abstract][Full Text] [Related]
14. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
Miyazaki O; Sekine K; Nakajima N; Ichimura E; Ebara K; Nagai D; Onda T; Miyakawa Y; Okamoto K; Morino T
Int J Cancer; 2014 Jan; 134(1):218-23. PubMed ID: 23775066
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
Matsumura Y
Adv Drug Deliv Rev; 2011 Mar; 63(3):184-92. PubMed ID: 20561951
[TBL] [Abstract][Full Text] [Related]
16. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
Zhang R; Saito R; Mano Y; Sumiyoshi A; Kanamori M; Sonoda Y; Kawashima R; Tominaga T
Drug Deliv; 2016 Oct; 23(8):2780-2786. PubMed ID: 26330269
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor model.
Vejjasilpa K; Nasongkla N; Manaspon C; Larbcharoensub N; Boongird A; Hongeng S; Israsena N
Exp Biol Med (Maywood); 2015 Dec; 240(12):1640-7. PubMed ID: 26080460
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
Hamaguchi T; Doi T; Eguchi-Nakajima T; Kato K; Yamada Y; Shimada Y; Fuse N; Ohtsu A; Matsumoto S; Takanashi M; Matsumura Y
Clin Cancer Res; 2010 Oct; 16(20):5058-66. PubMed ID: 20943763
[TBL] [Abstract][Full Text] [Related]
19. Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer.
Yanagihara K; Takigahira M; Kubo T; Ochiya T; Hamaguchi T; Matsumura Y
Ther Deliv; 2014 Feb; 5(2):129-38. PubMed ID: 24483192
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
